JNJ

238.91

+0.48%↑

UNH

276.31

+3.14%↑

TMO

542.91

-1.69%↓

ABT

109.17

+0.14%↑

ISRG

488.63

+1.9%↑

JNJ

238.91

+0.48%↑

UNH

276.31

+3.14%↑

TMO

542.91

-1.69%↓

ABT

109.17

+0.14%↑

ISRG

488.63

+1.9%↑

JNJ

238.91

+0.48%↑

UNH

276.31

+3.14%↑

TMO

542.91

-1.69%↓

ABT

109.17

+0.14%↑

ISRG

488.63

+1.9%↑

JNJ

238.91

+0.48%↑

UNH

276.31

+3.14%↑

TMO

542.91

-1.69%↓

ABT

109.17

+0.14%↑

ISRG

488.63

+1.9%↑

JNJ

238.91

+0.48%↑

UNH

276.31

+3.14%↑

TMO

542.91

-1.69%↓

ABT

109.17

+0.14%↑

ISRG

488.63

+1.9%↑

Search

CRISPR Therapeutics AG

Deschisă

SectorSănătate

48.01 1.72

Rezumat

Modificarea prețului

24h

Curent

Minim

45.52

Maxim

48.03

Indicatori cheie

By Trading Economics

Venit

102M

-106M

Vânzări

-3K

889K

Marjă de profit

-11,973.116

Angajați

393

EBITDA

101M

-101M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+38.79% upside

Dividende

By Dow Jones

Următoarele câștiguri

9 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-746M

4.9B

Deschiderea anterioară

46.29

Închiderea anterioară

48.01

Sentimentul știrilor

By Acuity

10%

90%

6 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 feb. 2026, 23:57 UTC

Câștiguri

Naver Has Record Year Despite Weaker Final Quarter

5 feb. 2026, 23:45 UTC

Acțiuni populare

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5 feb. 2026, 22:26 UTC

Câștiguri

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5 feb. 2026, 22:00 UTC

Câștiguri

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5 feb. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

5 feb. 2026, 23:47 UTC

Market Talk

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5 feb. 2026, 23:43 UTC

Market Talk

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5 feb. 2026, 23:37 UTC

Market Talk

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5 feb. 2026, 23:20 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5 feb. 2026, 23:11 UTC

Market Talk

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5 feb. 2026, 23:09 UTC

Câștiguri

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5 feb. 2026, 23:08 UTC

Câștiguri

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5 feb. 2026, 23:07 UTC

Câștiguri

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5 feb. 2026, 23:03 UTC

Market Talk
Câștiguri

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5 feb. 2026, 23:03 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5 feb. 2026, 23:00 UTC

Câștiguri

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5 feb. 2026, 23:00 UTC

Câștiguri

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5 feb. 2026, 22:59 UTC

Câștiguri

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5 feb. 2026, 22:59 UTC

Câștiguri

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5 feb. 2026, 22:52 UTC

Câștiguri

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5 feb. 2026, 22:45 UTC

Câștiguri

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5 feb. 2026, 22:37 UTC

Market Talk

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5 feb. 2026, 22:11 UTC

Câștiguri

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5 feb. 2026, 22:03 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5 feb. 2026, 22:01 UTC

Câștiguri

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5 feb. 2026, 21:59 UTC

Market Talk
Achiziții, Fuziuni, Preluări

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5 feb. 2026, 21:51 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5 feb. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

5 feb. 2026, 21:49 UTC

Câștiguri

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5 feb. 2026, 21:45 UTC

Câștiguri

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

38.79% sus

Prognoză pe 12 luni

Medie 69.63 USD  38.79%

Maxim 105 USD

Minim 40 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

11

Cumpărare

7

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

33.5 / 38.27Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

6 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat